{
  "id": "91f24cca-81da-45c2-97e4-296920974d19",
  "title": "Merck ends development of two antibody programs",
  "link": "https://seekingalpha.com/news/4387134-merck-ends-development-two-antibody-programs?utm_source=feed_news_all\u0026utm_medium=referral\u0026feed_item_type=news",
  "description": "",
  "author": "",
  "published": "Mon, 16 Dec 2024 19:43:49 -0500",
  "source": "https://seekingalpha.com/market_currents.xml",
  "categories": [
    "mrk"
  ],
  "byline": "Jonathan Block",
  "length": 475,
  "excerpt": "Merck is stopping development of two monoclonal antibody candidates for fixed-dose combinations with Keytruda due to trial data. Read more here.",
  "siteName": "Seeking Alpha",
  "favicon": "https://seekingalpha.com/samw/static/images/favicon-192x192.png",
  "text": "HealthcareJHVEPhoto/iStock Editorial via Getty Images Merck (NYSE:MRK) is ceasing development of two monoclonal antibody candidates it was eying as fixed-doses combinations with its blockbuster Keytruda (pembrolizumab). Vibostolimab is an anti-TIGIT antibody, while favezelimab is an anti-LAG-3 antibody. The fixed-dose combination of vibostolimab and Keytruda was Recommended For YouMore Trending NewsSee More »About MRK StockRelated StocksMRK-Trending AnalysisTrending News",
  "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420834981/image_1420834981.jpg?io=getty-c-w750",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv id=\"content\"\u003e\u003carticle data-test-id=\"grid-container\"\u003e\u003cdiv\u003e\u003cdiv data-test-id=\"grid-col-main\"\u003e\u003cdiv data-test-id=\"card-container\"\u003e\u003cheader\u003e\u003cdiv data-test-id=\"quick-links\"\u003e\u003cul\u003e\u003cli\u003e\u003ca data-test-id=\"theme-links-item\" href=\"https://seekingalpha.com/market-news/healthcare#source=section%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Ahealthcare%7Cfirst_level_url%3Anews\"\u003e\u003cspan\u003e\u003cspan\u003eHealthcare\u003c/span\u003e\u003c/span\u003e\u003c/a\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/div\u003e\u003c/header\u003e\u003cdiv\u003e\u003cdiv data-test-id=\"content-container\"\u003e\u003cfigure data-type=\"getty-image\"\u003e\u003cpicture\u003e\u003cimg src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420834981/image_1420834981.jpg?io=getty-c-w750\" alt=\"Merck headquarters in Kenilworth, New Jersey, August 23, 2022.\" data-id=\"1420834981\" data-type=\"getty-image\" width=\"1536px\" height=\"1024px\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420834981/image_1420834981.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420834981/image_1420834981.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420834981/image_1420834981.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420834981/image_1420834981.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420834981/image_1420834981.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420834981/image_1420834981.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420834981/image_1420834981.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420834981/image_1420834981.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 768px) calc(100vw - 36px), (max-width: 1024px) calc(100vw - 132px), (max-width: 1200px) calc(66.6vw - 72px), 600px\"/\u003e\u003c/picture\u003e\u003cfigcaption data-type=\"getty-image\"\u003e\u003cp\u003eJHVEPhoto/iStock Editorial via Getty Images\u003c/p\u003e\u003c/figcaption\u003e\u003c/figure\u003e\u003cul\u003e \u003cli\u003eMerck (\u003cspan\u003eNYSE:\u003ca title=\"Merck \u0026amp; Co., Inc.\" href=\"https://seekingalpha.com/symbol/MRK\"\u003eMRK\u003c/a\u003e\u003c/span\u003e) is ceasing development of two monoclonal antibody candidates it was eying as fixed-doses combinations with its blockbuster Keytruda (pembrolizumab).\u003c/li\u003e \u003cli\u003eVibostolimab is an anti-TIGIT antibody, while favezelimab is an anti-LAG-3 antibody.\u003c/li\u003e \u003cli\u003eThe fixed-dose combination of vibostolimab and Keytruda was\u003c/li\u003e \u003c/ul\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"recommended-section\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch4 data-test-id=\"recommended-for-you-card-title\"\u003eRecommended For You\u003c/h4\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv data-test-id=\"post-skeleton\"\u003e\u003c/div\u003e\u003c/div\u003e\u003csection data-test-id=\"trending-card-container\"\u003e\u003cdiv\u003e\u003cdiv\u003e\u003cp\u003e\u003ch2 data-test-id=\"trending-card-title\"\u003eMore \u003cspan id=\"trending-news\"\u003eTrending News\u003c/span\u003e\u003c/h2\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv data-test-id=\"post-skeleton\"\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv\u003e\u003cp\u003e\u003ca id=\"cardFooterSeeMore\" data-test-id=\"card-footer-link\" aria-labelledby=\"trending-news cardFooterSeeMore\" href=\"https://seekingalpha.com/market-news#source=first_level_url%3Anews%7Csection%3Amain_content%7Csection_asset%3Amore_trending_news%7Cbutton%3Amore\"\u003e\u003cspan\u003eSee More »\u003c/span\u003e\u003c/a\u003e\u003c/p\u003e\u003c/div\u003e\u003c/section\u003e\u003c/div\u003e\u003cdiv data-test-id=\"right-rail\"\u003e\u003cdiv data-test-id=\"about-symbol-card\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch3 data-test-id=\"about-symbol-card-title\"\u003eAbout MRK Stock\u003c/h3\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003cdiv data-test-id=\"about-symbol-chart\"\u003e\u003ctable data-test-id=\"table\"\u003e\u003cthead data-test-id=\"table-header\"\u003e\u003c/thead\u003e\u003ctbody data-test-id=\"table-body\"\u003e\u003c/tbody\u003e\u003c/table\u003e\u003cul\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"suggested-symbols-card\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch3 data-test-id=\"suggested-symbols-card-title\"\u003eRelated Stocks\u003c/h3\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003ctable data-test-id=\"table\"\u003e\u003cthead data-test-id=\"table-header\"\u003e\u003c/thead\u003e\u003ctbody data-test-id=\"table-body\"\u003e\u003ctr\u003e\u003ctd\u003e\u003ca data-test-id=\"mrk-link\" href=\"https://seekingalpha.com/symbol/MRK#source=first_level_url%3Anews%7Csection%3Aright_rail%7Csection_asset%3Arelated_stocks%7Csymbol%3Amrk%7Cline%3A1\"\u003eMRK\u003c/a\u003e\u003c/td\u003e\u003ctd\u003e-\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/table\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"trending-articles-cards-container\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch2 data-test-id=\"trending-articles-cards-title\" id=\"trending-articles-cards-container\"\u003eTrending Analysis\u003c/h2\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv data-test-id=\"post-skeleton\"\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"trending-news-cards-container\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch2 data-test-id=\"trending-news-cards-title\" id=\"trending-news-cards-container\"\u003eTrending News\u003c/h2\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003c/article\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "Less than 1 min",
  "publishedTime": "2024-12-17T00:43:49Z",
  "modifiedTime": "2024-12-16T19:44:17-05:00"
}
